Epica International, Inc. is excited to announce the successful completion of a funding round that raised an impressive $18 million. This significant investment underscores the immense potential of our pioneering technology and the increasing demand for advanced diagnostic solutions in healthcare. Epica is on the cutting edge of innovation with our state-of-the-art robotic CT platforms designed for a myriad of applications across both healthcare and industrial sectors. Our unique systems provide healthcare professionals with unparalleled soft-tissue and hard-tissue imagery, thereby enhancing diagnostic accuracy and improving patient outcomes dramatically. With this funding, we aim to accelerate the development and integration of our groundbreaking technologies, merging non-contact imaging with precision robotics. We have already witnessed remarkable results in experimental animal studies, validating the transformative potential of our systems within the medical field. This capital will be instrumental in scaling production, enhancing product features, and expediting our go-to-market strategies, ensuring that we deliver these revolutionary solutions to healthcare providers who are eager for improved diagnostic tools. As we step forward, our commitment to innovating the future of medicine鈥攂y harnessing the power of advanced imaging and autonomous technologies鈥攚ill remain our guiding principle. We envision a landscape where advanced robotic platforms redefine healthcare standards, delivering unprecedented accuracy and efficiency in diagnostics and treatment. We thank our partners and investors for their confidence and support as we embark on this exciting journey to revolutionize the way healthcare is delivered.








